Host Gene Status Influences Tumor Progression and Radiotherapy Response in -Driven Sporadic Pancreatic Cancers.

Heritable genetic variations can affect the inflammatory tumor microenvironment， which can ultimately affect cancer susceptibility and clinical outcomes. Recent evidence indicates that IDO2， a positive modifier in inflammatory disease models， is frequently upregulated in pancreatic ductal adenocarcinoma (PDAC). A unique feature of in humans is the high prevalence of two inactivating single-nucleotide polymorphisms (SNP)， which affords the opportunity to carry out loss-of-function studies directly in humans. In this study， we sought to address whether genetic loss of IDO2 may influence PDAC development and responsiveness to treatment. Transgenic and mice in which oncogenic KRAS is activated in pancreatic epithelial cells were evaluated for PDAC. Two patient data sets ( = 200) were evaluated for the two IDO2-inactivating SNPs together with histologic， RNA expression， and clinical survival data.